https://incephalo.com/  

8952 Schlieren, Wagistrasse 21

 office@incephalo.com

InCephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary Compartment Lock technology, also called C-Lock, retains biologics, that are applied locally behind the blood brain barrier, in the central nervous system (CNS) and once they leave the CNS, degrades them rapidly in the systemic compartment. Thereby it significantly improves local CNS therapy, a challenging task with regards to achieving high local concentration (for efficacy) and low systemic footprint (to reduce potential side effects). Especially the peripheral side effects still limit various promising candidates for the treatment of brain cancer or other neurological diseases.

https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

http://immunostherapeutics.com/  

8952 Schlieren, Wagistrasse 14

 info@immunostherapeutics.com

ImmunOs Therapeutics AG is a clinical-stage biotechnology company developing the next generation of novel immunotherapies that enhance the efficacy of market leading checkpoint inhibitors and costimulatory agonists for cancer therapy. The company is actively discussing and exploring new strategic collaborations with leading global pharmaceutical companies.

http://www.mabylon.com/  

8952 Schlieren, Wagistrasse 14

 +41 44 731 94 09
 info@mabylon.com

Mabylon is a biotechnology company spawned from the research of Prof. Adriano Aguzzi and his colleagues at the University of Zurich (UZH) and the University Hospital of Zurich (USZ). Mabylon is active in the field of human antibodies against prions, severe food allergies, and other intractable human diseases. Mabylon employs modern high-throughput technologies to screen for the presence of therapeutically relevant antibodies within large human populations. Up to 2'000 serum samples per day are screened using robots and miniaturized assays. Lymphocytes from seropositive carriers are then isolated, and their antibody genes are cloned.

http://www.novagotherapeutics.com  

8952 Schlieren, Wagistrasse 27

 info@novagotherapeutics.com

NovaGo Therapeutics is a biotech start-up company dedicated to the development of human antibody therapeutics that promote nerve repair and regeneration in the treatment of cerebral stroke and spinal cord injury. NovaGo is developing human antibody therapeutics against Nogo-A. Nogo-A is the most potent inhibitor of nerve fiber regeneration. Anti-NogoA treatment promotes recovery of function in several animal models of stroke. Novago Therapeutics' anti-NogoA treatment represents a novel, regenerative approach for stroke. Recovery of function in stroke and other neurological disorders will be a clinical breakthrough and have a major economic impact on health care.

https://memo-therapeutics.com/  

8952 Schlieren, Wagistrasse 27

 info@memo-therapeutics.com

Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Exploiting the power of our microfluidic single-cell molecular cloning and screening technologies we engage in antibody discovery across species and indications for proprietary and partnered projects. Our current pipeline features programmes in infectious diseases and immuno-oncology. MemoMAB discovery uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency and sensitivity. MemoMAB captures and preserves entire B cell repertoires from any donor species and any B cell type in recombinant form and displays them in mammalian cells, maintaining the cognate heavy and light chain pairing of the original B cells throughout the process.

https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.